◼ Archived
Business
Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint
Otsuka and Ionis report positive Phase 3 FUSION trial data for ulefnersen in treating a rare genetic form of ALS.
Ionis
7 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
🔮 fades ✗
Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial
Novartis and Ionis face setbacks as a high-stakes Phase 3 trial for an Lp(a) cardiovascular drug fails to meet its primary goals.
◼ Archived
Business
🔮 fades
The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High
Arrowhead Pharmaceuticals shares surge following positive Phase 3 clinical trial results for its triglyceride lowering drug, plozasiran.
◼ Archived
Business
🔮 fades
Why Arrowhead Shot Sky-High, While Chief Rival Ionis Toppled
Arrowhead stock surges to multi-year highs following a major Phase 3 trial success, while chief rival Ionis falls.
◼ Archived
Business
🔮 fades
Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump
AstraZeneca shares dropped six percent following a heart drug trial setback that simultaneously boosted rival stocks.
◼ Archived
Business
🔮 fades
AstraZeneca and Ionis Stocks Sink on Trial Miss and Analysts See an Overreaction
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
AstraZeneca, Ionis report major trial failure with heart disease drug
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.